Health Care • Biotechnology: Pharmaceutical Preparations
$2.08 ▼ -0.01
(-0.48%)
MKT CAP: $124.1M • VOL: 555.6K
52W L $2 52W H $8
FHTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $30.9M | $22.6M | $34.2M |
| YoY Revenue Growth % | +36.8% | -33.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$86.4M | -$102.7M | -$107.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$74.3M | -$86.6M | -$98.4M |
| EBITDA (Normalized) | -$86.3M | -$102.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$86.1M | -$100.4M | -$118.1M |
| Capital Expenditures (CapEx) | $50.0K | $906.0K | — |
| Free Cash Flow (FCF) | -$86.1M | -$101.3M | -$118.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $80.9M | $55.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$108.5M | -$45.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FHTX.